Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Active epithelial Hippo signaling in idiopathic pulmonary fibrosis
Jason J. Gokey, … , Anne-Karina T. Perl, Jeffrey A. Whitsett
Jason J. Gokey, … , Anne-Karina T. Perl, Jeffrey A. Whitsett
Published March 22, 2018
Citation Information: JCI Insight. 2018;3(6):e98738. https://doi.org/10.1172/jci.insight.98738.
View: Text | PDF
Research Article Cell biology Pulmonology

Active epithelial Hippo signaling in idiopathic pulmonary fibrosis

  • Text
  • PDF
Abstract

Hippo/YAP signaling plays pleiotropic roles in the regulation of cell proliferation and differentiation during organogenesis and tissue repair. Herein we demonstrate increased YAP activity in respiratory epithelial cells in lungs of patients with idiopathic pulmonary fibrosis (IPF), a common, lethal form of interstitial lung disease (ILD). Immunofluorescence staining in IPF epithelial cells demonstrated increased nuclear YAP and loss of MST1/2. Bioinformatic analyses of epithelial cell RNA profiles predicted increased activity of YAP and increased canonical mTOR/PI3K/AKT signaling in IPF. Phospho-S6 (p-S6) and p-PTEN were increased in IPF epithelial cells, consistent with activation of mTOR signaling. Expression of YAP (S127A), a constitutively active form of YAP, in human bronchial epithelial cells (HBEC3s) increased p-S6 and p-PI3K, cell proliferation and migration, processes that were inhibited by the YAP-TEAD inhibitor verteporfin. Activation of p-S6 was required for enhancing and stabilizing YAP, and the p-S6 inhibitor temsirolimus blocked nuclear YAP localization and suppressed expression of YAP target genes CTGF, AXL, and AJUBA (JUB). YAP and mTOR/p-S6 signaling pathways interact to induce cell proliferation and migration, and inhibit epithelial cell differentiation that may contribute to the pathogenesis of IPF.

Authors

Jason J. Gokey, Anusha Sridharan, Yan Xu, Jenna Green, Gianni Carraro, Barry R. Stripp, Anne-Karina T. Perl, Jeffrey A. Whitsett

×

Figure 8

Temsirolimus inhibits phosphorylation of S6, YAP transcriptional activity, and YAP-induced migration.

Options: View larger image (or click on image) Download as PowerPoint
Temsirolimus inhibits phosphorylation of S6, YAP transcriptional activit...
(A) Representative immunofluorescence microscopy was performed in HBEC3s transfected with GFP, YAP (WT), and YAP (S127A) and stained for p-S6 (green) and YAP (red) in the presence of temsirolimus (25 μg/ml) or DMSO (n = 5). Scale bars: 10 μm. (B) Western blot analysis of YAP following temsirolimus treatments shows reduced total YAP expression. (C) YAP, JUB, AXL, and CTGF RNAs were assessed after 48 hours (n = 3). RNA expression is normalized to DMSO-treated cells. (D) Time-lapse imaging of HBEC3s transduced with YAP (S127A) following treatment with temsirolimus at T = 0, 8, and 16 hours of a scratch assay (n = 3). *P < 0.05, assessed by ANOVA. HBEC3s, hTERT/CDK4–immortalized human bronchiolar epithelial cells.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts